Alzinova AB (SE:ALZ)

:ALZ

ALZ

Alzinova AB

RESEARCH TOOLSreports

Want to see SE:ALZ full AI Analyst Report?

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.38 - kr2.28

Previous CloseN/A

Volume98.89K

Average Volume (3M)655.64K

Market Cap

kr81.35M

Enterprise Valuekr40.74M

Total Cash (Recent Filing)kr11.38M

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.40

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding154,961,400

10 Day Avg. Volume664,473

30 Day Avg. Volume655,642

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage Balance SheetVery low debt-to-equity (~0.7%) materially reduces near-term solvency risk and preserves financial flexibility. For a clinical-stage biotech this allows continued R&D spending and negotiation of partnerships without immediate pressure from creditors, extending strategic options over months.

Focused Alzheimer’s Vaccine PipelineA clear, differentiated R&D focus on a disease-modifying Alzheimer’s vaccine (ALZ-101) concentrates scientific, regulatory, and business development efforts. This focused platform increases attractiveness for licensing/partnerships and aligns resources toward a single high-impact product over the medium term.

Improving Free Cash Flow Trend (versus Prior Period)An improving free cash flow trajectory, even from negative levels, signals that operational adjustments or cost discipline are having some effect. If sustained, this trend reduces future financing needs and supports longer-term program continuity and partner negotiations over the next several quarters.

Bears Say

Revenue Collapse To Near ZeroWith effectively no product revenue, the company lacks internal commercial cash generation and remains dependent on external financing, grants, or licensing. This structural absence of recurring revenues increases vulnerability to funding cycles and can pressure R&D continuity absent new partnerships.

Large, Persistent Cash Burn And Operating LossesSustained multi‑million operating losses and negative operating/free cash flow drive ongoing financing needs and elevate dilution risk. Persistent cash burn undermines long-term sustainability absent external funding or a material licensing deal, limiting strategic optionality over coming quarters.

Minimal Internal Scale And No Commercial OrganizationA very small staff (5 employees) and no marketed products imply heavy reliance on external partners and contractors for development and commercialization. That structural dependence can slow execution, increase partner negotiation leverage over the company, and raise operational risk during extended trials.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.38 and its highest was kr2.28 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr81.35M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is Aug 20, 2026 which is in 90 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on May 13, 2026. The company reported -kr0.056 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.056.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 154,961,400 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.056 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.704%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.